Future of GPR109A agonists in the treatment of dyslipidaemia

Diabetes, Obesity and Metabolism

Volumn 13, Issue 8, 2011, Pages 685-691

  Wanders, D ^a   Judd, R L ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Adipocytes; Cardiovascular disease; Cholesterol lowering therapy; Drug mechanism; GPR109A; Lipid lowering therapy; Niacin; Nicotinic acid; Pharmacology

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETYLSALICYLIC ACID; APELIN RECEPTOR; COMPLEMENTARY DNA; CYCLIC AMP PHOSPHODIESTERASE; DIACYLGLYCEROL ACYLTRANSFERASE 2; FATTY ACID; GPR109A; GUANINE NUCLEOTIDE BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PERTUSSIS TOXIN; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CHROMOSOME 12Q; DYSLIPIDEMIA; IMMUNOCOMPETENT CELL; KERATINOCYTE; LIPID BLOOD LEVEL; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 79959479456     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01400.x     Document Type: Review

References (68)

1. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480-486.
2. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955; 54: 558-559.
3. Soga T, Kamohara M, Takasaki J et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003; 303: 364-369.
4. Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 2003; 9: 352-355.
5. Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278: 9869-9874.
6. Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963; 173: 719-722.
7. Carlson LA, Oro L. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 1962; 172: 641-645.
8. Butcher RW, Baird CE, Sutherland EW. Effects of lipolytic and antilipolytic substances on adenosine 3', 5'- monophosphate levels in isolated fat cells. J Biol Chem 1968; 243: 1705-1712.
9. Aktories K, Jakobs KH, Schultz G. Nicotinic acid inhibits adipocyte adenylate cyclase in a hormone-like manner. FEBS Lett 1980; 115: 11-14.
10. Aktories K, Schultz G, Jakobs KH. Islet-activating protein prevents nicotinic acid-induced GTPase stimulation and GTP but not GTP gamma S-induced adenylate cyclase inhibition in rat adipocytes. FEBS Lett 1983; 156: 88-92.
11. Lorenzen A, Stannek C, Lang H, Andrianov V, Kalvinsh I, Schwabe U. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol 2001; 59: 349-357.
12. Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 2006; 126: 2637-2646.
13. Tang H, Lu JY, Zheng X, Yang Y, Reagan JD. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun 2008; 375: 562-565.
14. Hanson J, Gille A, Zwykiel S et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest 2010; 120: 2910-2919.
15. Li X, Millar JS, Brownell N, Briand F, Rader DJ. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. Biochem Pharmacol 2010; 80: 1450-1457.
16. Taggart AK, Kero J, Gan X et al. (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 2005; 280: 26649-26652.
17. Senior B, Loridan L. Direct regulatory effect of ketones on lipolysis and on glucose concentrations in man. Nature 1968; 219: 83-84.
18. Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab 2009; 296: E549-E558.
19. Plaisance EP, Grandjean PW, Brunson BL, Judd RL. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism 2008; 57: 404-409.
20. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
21. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NFkappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301.
22. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011; 121: 1163-1173.
23. Benyó Z, Gille A, Kero J et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005; 115: 3634-3640.
24. Benyó Z, Gille A, Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol 2006; 70: 1844-1849.
25. Walters RW, Shukla AK, Kovacs JJ et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 2009; 119: 1312-1321.
26. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-381.
27. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998; 82: 29U-34U.
28. Athyros VG, Tziomalos K, Mikhailidis DP et al. Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert Opin Pharmacother 2007; 8: 2267-2277.
29. Sturino CF, O'Neill G, Lachance N et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1, 2, 3, 4-tetrahydrocy clopenta[b]indol3-yl]-acetic acid (MK-0524). J Med Chem 2007; 50: 794-806.
30. Dean BJ, Chang S, Silva Elipe MV et al. Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans. Drug Metab Dispos 2007; 35: 283-292.
31. Kush D, Hu DY, Ye P et al. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology 2009; 114: 192-198.
32. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004; 45: 1835-1845.
33. Blum CB, Levy RI, Eisenberg S, Hall M, III, Goebel RH, Berman M. High density lipoprotein metabolism in man. J Clin Invest 1977; 60: 795-807.
34. Shepherd J, Packard CJ, Patsch JR, Gotto AM, Jr., Taunton OD. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979; 63: 858-867.
35. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001; 21: 1783-1789.
36. Kamanna VS, Vo A, Kashyap ML. Nicotinic acid: recent developments. Curr Opin Cardiol 2008; 23: 393-398.
37. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008; 101: 20B-26B.
38. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004; 67: 411-419.
39. Knowles HJ, te Poele RH, Workman P, Harris AL. Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol 2006; 71: 646-656.
40. van der Hoorn JW, de HW, Berbee JF et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008; 28: 2016-2022.
41. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redoxsensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009; 202: 68-75.
42. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol 2010; 30: 968-975.
43. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 2006; 27: 384-390.
44. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258: 94-114.
45. Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid- induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006; 103: 6682-6687.
46. Boatman PD, Richman JG, Semple G. Nicotinic acid receptor agonists. J Med Chem 2008; 51: 7653-7662.
47. O'Kane MJ, Trinick TR, Tynan MB, Trimble ER, Nicholls DP. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. Br J Clin Pharmacol 1992; 33: 451-453.
48. Santomauro AT, Boden G, Silva ME et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999; 48: 1836-1841.
49. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E1775-E1781.
50. Semple G, Skinner PJ, Gharbaoui T et al. 3-(1H-tetrazol-5-yl)-1, 4, 5, 6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J Med Chem 2008; 51: 5101-5108.
51. van HT, Brussee J, van den Nieuwendijk AM et al. Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem 2003; 46: 3945-3951.
52. Shen HC, Colletti SL. Novel patent publications on high-affinity nicotinic acid receptor agonists. Expert Opin Ther Pat 2009; 19: 957-967.
53. Schmidt D, Smenton A, Raghavan S et al. Anthranilic acid replacements in a niacin receptor agonist. Bioorg Med Chem Lett 2010; 20: 3426-3430.
54. Peters JU, Kuhne H, Dehmlow H et al. Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity. Bioorg Med Chem Lett 2010; 20: 5426-5430.
55. Tunaru S, Lattig J, Kero J, Krause G, Offermanns S. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol Pharmacol 2005; 68: 1271-1280.
56. Deng Q, Frie JL, Marley DM et al. Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. Bioorg Med Chem Lett 2008; 18: 4963-4967.
57. Lai E, Waters MG, Tata JR et al. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids and cutaneous flushing in humans. J Clin Lipidol 2008; 2: 375-383.
58. Ahmed K, Tunaru S, Offermanns S. GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors. Trends Pharmacol Sci 2009; 30: 557-562.
59. Ge H, Weiszmann J, Reagan JD et al. Elucidation of signaling and functional activities of an orphan GPCR, GPR81. J Lipid Res 2008; 49: 797-803.
60. Ahmed K, Tunaru S, Langhans CD et al. Deorphanization of GPR109B as a Receptor for the {beta}- oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. J Biol Chem 2009; 284: 21928-21933.
61. Cai TQ, Ren N, Jin L et al. Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res Commun 2008; 377: 987-991.
62. Liu C, Wu J, Zhu J et al. Lactate inhibits lipolysis in fat cells through activation of an orphan G-proteincoupled receptor, GPR81. J Biol Chem 2009; 284: 2811-2822.
63. Houghton CR, Hawkins RA, Williamson DH, Krebs HA. An explanation for the lowering of blood ketone- body concentrations in starved rats during short-term exercise. Biochem J 1971; 124: 56P-57P.
64. Gold M, Miller HI, Issekutz B Jr., Spitzer JJ. Effect of exercise and lactic acid infusion on individual free fatty acids of plasma. Am J Physiol 1963; 205: 902-904.
65. Boyd AE III, Giamber SR, Mager M, Lebovitz HE. Lactate inhibition of lipolysis in exercising man. Metabolism 1974; 23: 531-542.
66. Bjorntorp P. The effect of lactic acid on adipose tissue metabolism in vitro. Acta Med Scand 1965; 178: 253-255.
67. De PG, Cignarelli M, Nardelli G et al. Influence of lactate on isoproterenol-induced lipolysis and betaadrenoceptors distribution in human fat cells. Horm Metab Res 1989; 21: 210-213.
68. Ahmed K, Tunaru S, Tang C et al. An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metab 2010; 11: 311-319.